North America Cancer Biomarkers Market Size, Share & Industry Trends Analysis Report By Profiling Technologies, By Application, By Type, By Cancer Type, By Country and Growth Forecast, 2022 - 2028

North America Cancer Biomarkers Market Size, Share & Industry Trends Analysis Report By Profiling Technologies, By Application, By Type, By Cancer Type, By Country and Growth Forecast, 2022 - 2028

The North America Cancer Biomarkers Market would witness market growth of 15.4% CAGR during the forecast period (2022-2028).

Cancer biomarkers are biological compounds produced by tumor cells or human tissues in response to cancer, which is then evaluated and investigated as signs of malignant activity in the body. Cancer biomarkers are widely employed in the diagnosis and treatment of cancer patients. Biomarkers are employed in the follow-up surveillance and early diagnosis of suspected recurring diseases in cancer patients who have had curative surgery. In addition, the use of molecular biomarkers as part of normal diagnostic testing is a constant advancement in cancer diagnosis.

After skin cancer, breast cancer is the second most frequent type of cancer in the United States. Women are at a significant risk of developing breast cancer. Breast cancer is more common in women than in men, and male breast cancer is extremely rare. According to the Centers for Disease Control and Prevention (CDC), 236,968 women and 2,141 men were diagnosed with breast cancer in the United States in 2014, with 41,211 women and 465 men dying from the disease. According to 2015 figures from Cancer Research UK, new instances of breast cancer were diagnosed in the United Kingdom in 2015. Moreover, according to a comparable source, breast cancer is the most frequent cancer in the United Kingdom, accounting for a share of all new cancer cases in 2015.

According to the American Cancer Society, there were around 234,030 new instances of lung cancer diagnosed in the United States in 2018, with approximately 154,050 deaths attributable to lung cancer. Approximately 541,000 Americans have been diagnosed with lung cancer at a certain point in their life, as per the American Lung Association. Lung cancer has been diagnosed in the majority of patients in the last five years. In the United States, tens of thousands of people are treated for non-small cell lung cancer (NSCLC) each year. As a result of the rising prevalence of lung cancer, the market is predicted to rise. This can be because of the region's higher usage of cancer biomarkers. Moreover, the region's high cancer incidence rate promotes market expansion. In addition, in the region, numerous cancer biomarker testing is covered by health insurance. North America's supremacy can be ascribed to the larger adoption of modern technologies such as next-generation sequencing, as well as an increase in the number of research studies proving the efficacy of biomarkers in drug discovery and development, as well as cancer detection.

The US market dominated the North America Cancer Biomarkers Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $8,674.7 million by 2028. The Canada market is poised to grow at a CAGR of 18.1% during (2022 - 2028). Additionally, The Mexico market would display a CAGR of 17% during (2022 - 2028).

Based on Profiling Technologies, the market is segmented into Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, and Cytogenetics. Based on Application, the market is segmented into Diagnostics, Research & Development, Prognostics, Risk Assessment, and Others. Based on Type, the market is segmented into Protein, Genetic, and Others. Based on Cancer Type, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Thyroid Cancer, Melanoma & Leukemia, Kidney & Bladder Cancer, Non-Hodgkin's Lymphoma, Prostate Cancer, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include BioMérieux S.A., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Abbott Laboratories, Thermo Fisher Scientific, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., Qiagen N.V., Agilent Technologies, Inc., and Merck & Co., Inc.

Scope of the Study

Market Segments covered in the Report:

By Profiling Technologies

• Omics Technologies
• Imaging Technologies
• Immunoassay
• Bioinformatics
• Cytogenetics

By Application

• Diagnostics
• Research & Development
• Prognostics
• Risk Assessment
• Others

By Type

• Protein
• Genetic
• Others

By Cancer Type

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Thyroid Cancer
• Melanoma & Leukemia
• Kidney & Bladder Cancer
• Non-Hodgkin's Lymphoma
• Prostate Cancer
• Others

By Country

• US
• Canada
• Mexico
• Rest of North America

Companies Profiled

• BioMérieux S.A.
• F. Hoffmann-La Roche Ltd.
• Becton, Dickinson and Company
• Abbott Laboratories
• Thermo Fisher Scientific, Inc.
• Illumina, Inc.
• Bio-Rad Laboratories, Inc.
• Qiagen N.V.
• Agilent Technologies, Inc.
• Merck & Co., Inc.

Unique Offerings from KBV Research

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free